Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The t(2;5) in human lymphomas

M E Kadin1, S W Morris

  • 1Department of Pathology, Beth Israel Hospital and Harvard Medical School, Boston, MA 02115, USA. mkadin@bidmc.harvard.edu

Leukemia & Lymphoma
|July 31, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Reed-Sternberg Cell, An Activated T-cell? The Evidence Has Come Full Circle.

Leukemia & lymphoma·2016
Same author

KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.

The British journal of dermatology·2016
Same author

CD30-rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right.

The British journal of dermatology·2015
Same author

γδ T-cell-rich variants of pityriasis lichenoides and lymphomatoid papulosis: benign cutaneous disorders to be distinguished from aggressive cutaneous γδ T-cell lymphomas.

The British journal of dermatology·2014
Same author

708 Common and 2010 rare DISC1 locus variants identified in 1542 subjects: analysis for association with psychiatric disorder and cognitive traits.

Molecular psychiatry·2013
Same author

NPM-ALK Reverse Transcriptase-Polymerase Chain Reaction Analysis for Detection of the t(2;5) Translocation of Non-Hodgkin's Lymphoma.

Methods in molecular medicine·2011
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

The t(2;5) translocation creates the NPM-ALK fusion protein, found in CD30+ anaplastic large-cell lymphomas (ALCL). This protein

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Anaplastic large-cell lymphoma (ALCL) is a subtype of non-Hodgkin's lymphoma (NHL).
  • A specific translocation, t(2;5)(p23;q35), is recurrent in CD30+ ALCL.
  • This translocation results in a novel fusion protein, NPM-ALK.

Purpose of the Study:

  • To investigate the presence and significance of the NPM-ALK fusion protein in various lymphoma subtypes.
  • To understand the expression patterns of NPM-ALK in relation to patient demographics and clinical features.
  • To explore the diagnostic and potential prognostic implications of NPM-ALK in lymphoma.

Main Methods:

  • Reverse transcriptase-polymerase chain reaction (RT-PCR) for NPM-ALK transcripts.
  • Genomic DNA-PCR and fluorescence in situ hybridization (FISH) for chromosomal abnormalities.

Related Experiment Videos

  • Immunohistochemistry for detection of the p80 protein.
  • RNA in situ hybridization to assess gene expression.

    • Main Results:

    • NPM-ALK expression is characteristic of CD30+ ALCL, particularly in younger patients with advanced disease.
    • Expression is less common in older patients and pleomorphic ALCL.
    • NPM-ALK is occasionally found in CD30-negative B-cell lymphomas but rarely in Hodgkin's disease.
    • Studies suggest NPM-ALK expression may be associated with better survival, requiring further validation.

    Conclusions:

    • The t(2;5) translocation and NPM-ALK fusion protein are key molecular events in a subset of ALCL.
    • NPM-ALK expression has distinct patterns across lymphoma types and patient groups.
    • Further prospective studies are needed to confirm the prognostic value of NPM-ALK in ALCL.